Andrew J Sauer MD presents to a crowd on on quadruple medial therapy uptake across regions with IMPLEMENT-HF ❤️🔥 American College of Cardiology #ACC24 AHAMeetings John Spertus Mikhail Kosiborod Mirza Khan Evan O'Keefe Charles F. Sherrod IV, MD MSc Dan Nguyen Brett Sperry, MD Healthcare Institute for Innovations in Quality Saint Luke's Mid America Heart Institute Saint Luke's

Dr. Andrew J Sauer MD from Saint Luke's Mid America Heart Institute presented a hopeful message today at #ACC24, sharing a report from American Heart Association’s IMPLEMENT-HF initiative. Learn more here: heart.org/en/professiona…

Participated in 2 Live cases for #ACC24 🫀 Peripheral: CTO L-SFA (ADR) 🫀 Coronary: CTO PCI RCA (retrograde, guideliner facilitated X-CART via tortuous epicardial collaterals) 🫶🏼 learning from the best🌟 Saint Luke's Mid America Heart Institute J Aaron Grantham JAG Dany Jacob Matthew Bunte

Proud of Dr Uttsav Sandesara, our Heart Failure fellow at Saint Luke's Mid America Heart Institute, for doing an interview with @tctmd on his experience training as an internist training in HF Eiran Gorodeski, MD, MPH

Our fellow Merrill Blue, an ultra marathoner herself, teaching us about the effects of endurance exercise on cardiovascular health

Star fellow Amanda Heuszel teaching us how to teach! Excellent pearls from someone who received her masters in medical education during CV fellowship and will join us next year in a leadership capacity at UMKC School of Medicine

In ATTR-ACT, we found that renal function deteriorates over time in patients with ATTR-CM, and tafamidis treatment was associated with a reduction in this deterioration, and a higher incidence of improved eGFR and CKD staging over 30 months vs placebo. sciencedirect.com/science/articl…

The Mummy Returns! 💀☠️👻 Randall Thompson and Gregory S Thomas MD describe atherosclerosis in 237 mummies from 7 different cultures spanning >4500 years. Atherosclerotic calcifications have been found in all populations and rates are similar in males and females. academic.oup.com/eurheartj/adva…

Happy to share that the Saint Luke's Mid America Heart Institute team was the first in the region to perform transcatheter tricuspid valve replacement using the Edwards Evoque Valve. This device is commercially approved to treat TR and improve symptoms of heart failure.  Saint Luke's Adnan Chhatriwalla

A few of our phenomenal fellows celebrating with some pickleball after surviving echo boards! Suchith Vuppala Andy Godwin Amanda Heuszel Mark Metzinger, Angel Garcia Charles F. Sherrod IV, MD MSc Dan Nguyen Saint Luke's

Healthy vs pathological microvascular aging? New research showing myocardial blood flow reserve is higher in young males compared with females, and decreases with age in both sexes. Saint Luke's Mid America Heart Institute Saint Luke's CircImaging ahajournals.org/doi/10.1161/CI…

Excited to be joining Saint Luke’s Mid America Heart Institute in Kansas City to help care for ACHD patients at the only accredited program in the Missouri/Kansas area Saint Luke's Mid America Heart Institute ACHA

Applying to advanced #HeartFailure fellowship this year? Consider applying to join us at University of Missouri-Kansas City School of Medicine program at Saint Luke's Mid America Heart Institute Saint Luke's Andrew J Sauer MD Michael Nassif John Spertus Mikhail Kosiborod saintlukeskc.org/advanced-heart…

Here are some reasons why you should train with us in Cardiovascular Disease at the University of Missouri-Kansas City School of Medicine program Saint Luke's Mid America Heart Institute Saint Luke's!

Proof I made it to European Society of Cardiology Let’s go! Check out JACC Journals publications our team is releasing soon during London sessions. jacc.org/events/confere… Mikhail Kosiborod John Spertus Saint Luke's Mid America Heart Institute Saint Luke's

Semaglutide and obesity related HFpEF Patients with atrial fibrillation and obesity HFpEF are generally more burdened/congested at baseline and also may benefit more from GLP1 in health status and walking distance. Mikhail Kosiborod Saint Luke's Mid America Heart Institute jacc.org/doi/10.1016/j.…

Inflammation reduction by semaglutide as measured by CRP tracks with magnitude of NTproBNP reduction.

Semaglutide and obesity HFpEF Echo markers Improved LA volume reduction and markers of diastolic function with GLP1 compared to placebo. Muthu Vaduganathan BiykemBozkurt Mikhail Kosiborod

CV outcomes from FLOW trial. Semaglutide vs placebo focused on patients with HF within larger population of T2DM and CKD.

Pooled analysis of patients with HFpEF in STEP-HFpEF, SELECT, and FLOW Mikhail Kosiborod Saint Luke's Mid America Heart Institute Saint Luke's Muthu Vaduganathan